We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Ms
Sarah
Bradley
+44 (0)141 301 7540
Sarah.Bradley@glasgow.ac.uk
Ms
Sarah
Bradley
+44 (0)141 301 7540
sarah.bradley@glasgow.ac.uk
Metastatic pancreatic cancer
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
You can take part if:
You may not be able to take part if:
Current exclusion criteria as of 12/03/2024:
1. Prior treatment with nab-paclitaxel or oxaliplatin2. Prior chemotherapy for metastatic pancreatic cancer3. Known hypersensitivity for any component of any study drug4. Active infection including Herpes Zoster and chickenpox5. Current neuropathy ≥ grade 26. Uncontrolled brain metastatsis or mental illness7. Uncontrolled congestive heart failure (CHF), or history of myocardial ischemia (MI), unstable angina, stroke, or transient ischemia within previous 6 months.8. Uncontrolled serious contraindicated medical condition or illness9. Known or suspected dihydropyrimidine (DPD) deficiency10. Pregnant of breastfeeding11. History of physical or psychiatric disorder that would prevent informed consent and compliance with protocol12. Administration of any investigational drug within 28 days or 5 half-lives, whichever is longer, of receiving the first dose of trial treatment13. Any systemic anti-cancer therapy, or major surgery within 28 days of randomisation14. Any minor surgery or radiotherapy within 7 days of randomisation15. Any psychological, familial, sociological or geographical consideration potentially hampering compliance with the trial protocol and follow up schedule.16. Any patients receiving treatment with brivudin, sorivudin and analogues17. History of another malignancy in the last 3 years (other than treated squamous/basal cell skin cancer, treated early-stage cervical cancer or treated/biochemically-stable, organ-confined prostate cancer)19. Any patient with severe diarrhoea (defined as ≥grade 3 diarrhoea despite maximum supportive measures and exclusion of underlying infection
_____
Previous exclusion criteria:
1. Prior treatment with nab-paclitaxel or oxaliplatin2. Prior chemotherapy for metastatic pancreatic cancer3. Known hypersensitivity for any component of any study drug4. Active infection including Herpes Zoster and chickenpox5. Current neuropathy ≥ grade 26. Uncontrolled brain metastatsis or mental illness7. Uncontrolled congestive heart failure (CHF), or history of myocardial ischemia (MI), unstable angina, stroke, or transient ischemia within previous 6 months.8. Uncontrolled serious contraindicated medical condition or illness9. Known or suspected dihydropyrimidine (DPD) deficiency10. Pregnant of breastfeeding11. History of physical or psychiatric disorder that would prevent informed consent and compliance with protocol12. Administration of any investigational drug within 28 days or 5 half-lives, whichever is longer, of receiving the first dose of trial treatment13. Any systemic anti-cancer therapy, or major surgery within 28 days of randomisation14. Any minor surgery or radiotherapy within 7 days of randomisation15. Any psychological, familial, sociological or geographical consideration potentially hampering compliance with the trial protocol and follow up schedule.16. Any patients receiving treatment with brivudin, sorivudin and analogues17. History of another malignancy in the last 5 years (other than treated squamous/basal cell skin cancer, treated early-stage cervical cancer or treated/bio18. Chemically-stable, organ-confined prostate cancer)19. Any patient with severe diarrhoea (defined as ≥grade 3 diarrhoea despite maximum supportive measures and exclusion of underlying infection
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
This information has not yet been provided by the study team. You'll have an opportunity to discuss any risks and benefits that may be associated with this study prior to consenting to taking part.
Ms
Sarah
Bradley
+44 (0)141 301 7540
sarah.bradley@glasgow.ac.uk
Ms
Sarah
Bradley
+44 (0)141 301 7540
Sarah.Bradley@glasgow.ac.uk
The study is sponsored by NHS Greater Glasgow and Clyde and funded by Cancer Research UK; Celgene.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
